AbbVie's Emblaveo, a groundbreaking aztreonam-avibactam combination, receives FDA approval for treating complicated intra-abdominal infections with limited treatment options.
Antabio's MEM-ANT3310, a novel antibacterial combination, has successfully completed its Phase 1 clinical trial in healthy volunteers, demonstrating good tolerability.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.